Ségolène Martin

Look at this smile 🎈

Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism" —the 1st human to undergo custom genome editing —outgrowth of decades of NIH funded research nejm.org/doi/full/10.10… nejm.org/doi/full/10.10… @NEJM nytimes.com/2025/05/15/hea…

Have your say ! Call for evidence for the Biotech Act: ec.europa.eu/info/law/bette… The biotech sector plays a critical role in several areas of the EU economy. It is research-driven, fast-moving and requires substantial public and private investments.

Insightful 🏷️

Good news everyone! The unpopular and seemingly irrelevant lecture I give in my health econ class on "Most favored nations agreements" just became prophetically relevant. Bad news everyone! This is a terrible policy. 🧵

Everyone needs to hear this…

ANY foreign clinical trial site that's part of NIH-funded research may be forced to shut down under new 'America First'-driven policy: statnews.com/2025/05/02/nih…

The NeurIPS 2025 Creative AI Track is now inviting research papers and artworks that explore cutting edge applications of AI and ML in art, design, and creative practice. This year, we welcome submissions on the theme of "Humanity". Read more in our Call for Creative AI 2025: neurips.cc/Conferences/20…

3. Rare Disease (cited 15 and 72 patients worldwide for example) may get approval based on mechanism of action only - then track and follow patients to see if drug works.

A smart foreign-born undergrad at a US university asked me if he should go to the UK to start his startup because of the random deportations here. I said that while the median startup wasn't taking things to this extreme yet, it would be an advantage in recruiting.

No! This photo is not AI edited: a heart-shaped sun ray appeared right during our last team photo!❤️ Meet below a team of people working every day with a lot of ❤️, talent, and AI - to accelerate the discovery of therapies for patients who need them the most.

What’s a life-saving medical fact everyone should know?

This looks extremely interesting 🤓

Today, we at OpenAI launched Deep Researcher and I wanted to share a deeply personal story about how amazing this tool is and how it will change the world. Trigger warning, related to cancer....1/9

Hey Twitter, we are disclosing our biotech pipeline, and there is even a bonus for drug discovery experts. Cancer, Rare Cancers, Rare Neuromuscular disorders, Neurology and Ion Channels are some of our areas of focus.

@InsermTransfert @CanaudLab @CatherineClusel @DariaJulkowska Bravo 👏

🗓 mardi 10 décembre : Prix Inserm 2024 ✨ 📢 Les équipes d’Inserm Transfert étaient présentes pour cette soirée qui a mis à l'honneur la recherche scientifique de l'Inserm. 🏆 Nous adressons nos félicitations au Professeur Guillaume Canaud @CanaudLab pour son Prix Innovation ! Inserm Transfert est fier d’accompagner Guillaume Canaud dans ses projets de recherche et de valorisation sur les maladies du syndrome d'hypercroissance dysharmonieuse dont fait partie le syndrome de CLOVES 🏆 Bravo à Vincent Prévot pour son Prix Recherche ! Inserm Transfert accompagne Vincent Prévot depuis de nombreuses années, sur la valorisation de ses projets, la contribution à son projet européen #H2020 #miniNO sur la mini puberté ainsi que son projet de start-up GnRHope qui a pour objectif de transformer la prise en charge des patients porteurs de troubles du neurodéveloppement, ceci à travers notre Parcours Pre-Entrepreneurial et notre programme de Mentorat. 🏆 Enfin félicitations à @DariaJulkowska pour son Prix Appui à la recherche ! Inserm Transfert a accompagné Daria Julkowska durant 5 ans dans le projet European Joint Programme on Rare Diseases (EJP RD), qui visait à créer un écosystème efficace de recherche sur les maladies rares et récemment dans le montage du projet @ERDERA_org , une alliance européenne pour la recherche sur les maladies rares. 👏 Félicitations aux autres lauréats : 👉 Stéphanie Debette, Grand Prix Inserm 👉 Jonathan Bernard, pour le Prix Science et société-Opecst 👏Encore bravo à toutes les équipes ! 👨‍🔬👩‍🔬 Vive la Science ! Vive la Recherche ! Pour découvrir les lauréats : #recherche" target="_blank" rel="nofollow noopener">inserm.fr/actualite/prix… #innovation #santé #science

Can an AI for human drug discovery also excel in plant drug discovery? The answer is yes! This is what our COO @Nico_Maignan explained at his lecture "Unlocking & Accelerating Drug Discovery with Artificial Intelligence: The Kantify Approach." held by our partner @IBMCP 🙏🌿

Scared to share this after 10 freaking years of waiting but here we go: We found that temperature *perception* can change the next generations, even when “it’s just in the parents' head”. Read how C. elegans neurons control epigenetic inheritance! biorxiv.org/content/10.110…

Huge randomized trial of AI boosts discovery “Teams that were randomly assigned to use the tool discovered 44% more new materials and filed 39% more patent applications than did the ones that stuck to their standard workflow” nature.com/articles/d4158…

Today, we're unveiling the latest small molecule drug screened by our AI, Sapian. Many of you are familiar with this medication-it was the 169th most prescribed drug in the United States in 2022, with over 3 million prescriptions. This widely used drug is Diazepam, aka Valium.